Use and tolerability of imatinib mesylate (Gleevec) in patients with Philadelphia-positive chronic myeloid leukemia during the first 100 days following bone marrow or stem cell transplantation

Trial Profile

Use and tolerability of imatinib mesylate (Gleevec) in patients with Philadelphia-positive chronic myeloid leukemia during the first 100 days following bone marrow or stem cell transplantation

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Jul 2012

At a glance

  • Drugs Imatinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 26 May 2009 Actual end date is October 2007 as reported by ClinicalTrials.gov.
    • 09 Oct 2007 Status change from recruiting to completed
    • 20 Jul 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top